Reconstitute in sterile 18MOhm/cm H2O at not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
Lanreotide is a a synthetic cyclic octapeptide used as a drug in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. Lanreotide is a synthetic analogue of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Lanreotide binds to the same receptors as somatostatin, although with higher affinity to peripheral receptors, and has similar activity. However, while somatostatin is quickly broken down in the body (within minutes), lanreotide has a much longer half-life, and produces far more prolonged effects.
References for Lanreotide peptide (ab73337)
has not yet been referenced specifically in any publications.
Publishing research using ab73337? Please let us know so that we can cite the reference in this datasheet.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Get resources and offers direct to your inboxSign up